Summary • Cartesian Therapeutics (RNAC) shares rose 6.9% in pre-market trading, reaching $7.18. • Director Timothy C. Barabe purchased 30,000 shares at $6.86, indicating possible insider confidence. • ...

New funding totaling 3 million euros for cancer care in Ethiopia and research in Germany ...

Fintel reports that on November 19, 2025, HC Wainwright & Co. maintained coverage of Cartesian Therapeutics (NasdaqGM:RNAC) with a Buy recommendation. Analyst Price Forecast Suggests 391.45% Upside As ...

H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $30 from $40 and keeps a Buy rating on the shares. The firm ...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...

Cartesian Therapeutics develops mRNA cell therapies for autoimmune diseases, leveraging three modalities: mRNA CAR-T, mRNA MSC, and mRNA in situ. Lead asset Descartes-08 targets myasthenia gravis, ...

(RTTNews) - Cartesian Therapeutics, Inc. (RNAC) Tuesday announced positive updated data from the Phase 2b trial of Descartes-08 in people with myasthenia gravis (MG), an autoimmune disease that causes ...

The Company will host a conference call and webcast to discuss the updated data, as well as details regarding the design of its planned Phase 3 trial, on Tuesday, December 3, 2024, at 7:30 a.m. ET.